SCHEMBL3335376

SCHEMBL3335376

CN(C)CCCOc1nc(N)nc2ccc(-c3cccc(C(F)(F)F)c3)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.42
ADORA1 P30542 2/20 0.42
TOP2A P11388 1/20 0.41
LCK P06239 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
PIM1 P11309 2/20 0.39
PIM3 Q86V86 2/20 0.39
CACNA1B Q00975 1/20 0.39
NUDT1 P36639 1/20 0.39
RAD52 P43351 1/20 0.39
APP P05067 1/20 0.39
RXFP1 Q9HBX9 1/20 0.38
LSS P48449 1/20 0.38
ATM Q13315 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340191 0.85 ALOX5AP (0.41) ADORA2AADORA1TOP2APIM1PIM3
SCHEMBL3337194 0.81 TOP2A (0.41) ADORA2AADORA1TOP2AHRH3PIM1
SCHEMBL3340124 0.81 TOP2A (0.43) TOP2AHRH3PIM1PIM3NUDT1
SCHEMBL3341480 0.81 HRH3 (0.50) TOP2AHRH3PIM1NUDT1LSS
SCHEMBL3336783 0.79 HRH3 (0.42) ADORA2AADORA1TOP2AHRH3PIM1
SCHEMBL3331691 0.78 ADORA2A (0.43) ADORA2AADORA1LCKAPPATM
SCHEMBL3337374 0.78 MEN1 (0.47) ADORA2AADORA1RXFP1CYP1A2CYP3A4
SCHEMBL3338234 0.78 TRIM58 (0.48) ADORA2AADORA1LCKAPPCYP1A2
SCHEMBL5139806 0.76 TOP2A (0.39) ADORA2AADORA1TOP2AHRH3PIM1
SCHEMBL3335114 0.76 TOP2A (0.46) ADORA2ATOP2AHRH3PIM1NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 ADORA2A 1968/4885ADORA1 870/4885TOP2A 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.